ALKBH5 and neoplasm: (157) have developed CRISPR/Cas9 fusions with a single chain m6A methyltransferase ALKBH5 or FTO to achieve demethylation of RNAs at site-specific, which broadens the scope of RNA engineering and facilitates mechanistic understanding of epitranscriptome in tumor research.